Back to Archived Journals » Comparative Effectiveness Research » Volume 8

Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China [Corrigendum]

Authors Li J, Ren HY, Zhang J, Dong P, Wang Y, Stevens AL, Han Y, Huang M

Received 8 September 2017

Accepted for publication 8 September 2017

Published 24 January 2018 Volume 2018:8 Pages 1—2

DOI https://doi.org/10.2147/CER.S151220


Li J, Ren HY, Zhang J, et al. Comparative Effectiveness Research. 2017;7:1–9

On page 8, Acknowledgments section, “The abstract of this study was presented at the ISPOR 18th Annual European Congress as a poster presentation with interim findings. The poster’s abstract was published in “Poster Abstracts” in Value In Health 2015 November issue.21” should have been “The abstract of this study was presented at the ISPOR 18th Annual European Congress as a poster presentation with interim findings. The poster’s abstract was published in “Poster Abstracts” in Value In Health 2015 November issue.21 The authors thank Dr. Liheng Ma from China Pfizer Medical, who provided medical insight in the study design phase and helped to secure the research funding. This work would not have been possible without such support.”

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]